RIGEL PHARMACEUTICALS INC

For the period ended Dec 31, 2024. Filed Mar 4, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 4, 2025

RIGL$42.05+6.1%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Statements of Operations

(In thousands, except per share amounts)


· · Year Ended December 31,
· 2024 · 2023 · 2022
Revenues:
Product sales, net	$144,902	$104,294	$76,718
Contract revenues from collaborations	34,376	11,488	39,024
Government contracts	—	1,100	4,500
Total revenues	179,278	116,882	120,242
Costs and expenses:
Cost of product sales	18,647	7,110	1,749
Research and development	23,380	24,522	60,272
Selling, general and administrative	113,059	105,741	112,451
Restructuring charges	—	—	1,320
Total costs and expenses	155,086	137,373	175,792
Income (loss) from operations	24,192	(20,491)	(55,550)
Interest income	2,092	2,272	684
Interest expense	(7,918)	(6,872)	(3,707)
Income (loss) before income taxes	18,366	(25,091)	(58,573)
Provision for income taxes	881	—	—
Net income (loss)	$17,485	$(25,091)	$(58,573)

Net income (loss) per share(1)
Basic	$0.99	$(1.44)	$(3.44)
Diluted	$0.99	$(1.44)	$(3.44)
Weighted average shares used in computing net income (loss) per share (1)
Basic	17,579	17,401	17,049
Diluted	17,687	17,401	17,049

(1)	Share and per share amounts have been restated to reflect the 1-for-10 reverse stock split effected on June 27, 2024 on a retroactive basis for the respective periods presented.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.